TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35305596
Drug: Dacomitinib (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dacomitinib (45 mg/day)
Study: 32142084
Drug: 1 gram
Normalized name: guar gum 1 gram ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 gram of pure eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), or docosahexaenoic acid (DHA) daily for 6 days
Study: 36414937
Drug: Supplementary suckling
Normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplementary suckling technique with high or low protein milk-based formula supplement
Study: 36463226
Drug: CC-486 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-486 (300 mg daily on days 1-21 of a 28-day cycle)
Study: 32364091
Drug: Casein protein
Normalized name: caseins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casein protein (CP) 25 g
Study: 33159632
Drug: Pediatric Autism
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pediatric Autism Spectrum Therapy Observation System (PASTOS)
Study: 33159632
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy (manual-based)
Study: 34606846
Drug: Nonsteroidal anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroidal anti-inflammatory drugs (NSAIDs)
Study: 616996904
Drug: Bisoprolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol (10 mg)
Study: 32513936
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (OT), 40 IU, administered as a single acute dose over 18–26 min post dosing.
Study: 32513936
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered as a control treatment.
Study: 35253516
Drug: 50 µg
Normalized name: penicillin G 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 µg LSD
Study: 35253516
Drug: 75 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 µg LSD
Study: 35253516
Drug: 100 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 µg LSD
Study: 35253516
Drug: 50 µg
Normalized name: penicillin G 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 µg followed by 75 µg LSD (1 week apart)
Study: 35253516
Drug: Placebo followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo followed by 75 µg LSD (1 week apart)
Study: 32307626
Drug: Poor oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poor oral health knowledge, high dental anxiety, brushing teeth less than once a day, and regular consumption of chocolates or biscuits.
Study: 33402037
Drug: Any antithrombotic
Normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any antithrombotic therapy
Study: 33649451
Drug: No bladder
Approvals — FDA: no, EMA: no, PMDA: no
Description: No bladder antimuscarinic treatment (control group).
Study: 32909511
Drug: Trimetazidine (TMZ),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (TMZ), 20 mg thrice daily orally 24 hours before and 72 hours after PCI
Study: 39454963
Drug: Metacognitive Interpersonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metacognitive Interpersonal Therapy (MIT)
Study: 35221673
Drug: Tadalafil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil (5 mg) alone
Study: 35221673
Drug: Amlodipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (10 mg) alone
Study: 35221673
Drug: Combined administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined administration of tadalafil and amlodipine
Study: 32128907
Drug: Topical rapamycin
Normalized name: natamycin Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical rapamycin solution (1 mg/mL) applied twice daily for 3 months
Study: 32128907
Drug: Betamethasone dipropionate
Normalized name: Betamethasone Dipropionate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone dipropionate ointment 0.05% in Orabase® applied twice daily for 3 months
Study: 32460815
Drug: Defining a
Normalized name: refined almond oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Defining a minimum expertise level for treatment provider
Study: 36088327
Drug: sST2 ≥
Approvals — FDA: no, EMA: no, PMDA: no
Description: sST2 ≥ 32.0 ng/mL
Study: 36088327
Drug: sST2 16.5–32.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: sST2 16.5–32.0 ng/mL
Study: 36088327
Drug: NT-proBNP ≥
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT-proBNP ≥ 337 ng/L
Study: 36088327
Drug: NT-proBNP 89–337
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT-proBNP 89–337 ng/L
Study: 36088327
Drug: hs-cTnI ≥
Approvals — FDA: no, EMA: no, PMDA: no
Description: hs-cTnI ≥ 7.8 ng/L
Study: 35683592
Drug: Cell therapy
Normalized name: hRPE cell therapy
DrugBank: ASP-7317 (DB18549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cell therapy
Study: 35143411
Drug: 500 mg/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/L buffered MS‐222 for 15 minutes
Study: 35143411
Drug: 1000 mg/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg/L buffered MS‐222 for 15 minutes
Study: 35143411
Drug: 1000 mg/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg/L buffered MS‐222 for 15 minutes, then placed in freshwater for 3 hours
Study: 35143411
Drug: 1000 mg/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg/L buffered MS‐222 for 15 minutes, then placed in freshwater for 18 hours
Study: 35143411
Drug: 1000 mg/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg/L buffered MS‐222 for 60 minutes, then placed in freshwater for 3 hours
Study: 35285282
Drug: Educational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Educational intervention (ten 1-hour sessions, twice weekly)
Study: 32861841
Drug: Family-focused therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-focused therapy
Study: 32421353
Drug: Intrapleural fibrinolytic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapleural fibrinolytic therapy (IPFT)
Study: 32014032
Drug: S44819 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: S44819 150 mg bid
Study: 32014032
Drug: S44819 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: S44819 300 mg bid
Study: 32969391
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate intranasal spray
Study: 36054369
Drug: Sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium chloride intranasal spray (placebo)
Study: 33508918
Drug: nCRT (XELOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: nCRT (XELOX chemotherapy: capecitabine + oxaliplatin) with concurrent radiotherapy (45 Gy, 25 times, 1.8 Gy/d, 5 times/week)
Study: 33508918
Drug: nCRT (XELOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: nCRT (XELOX chemotherapy: capecitabine + oxaliplatin)
Study: 36115523
Drug: Deucravacitinib 6
Normalized name: deucravacitinib 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deucravacitinib 6 mg daily
Study: 34639109
Drug: Vaginal injection
Normalized name: Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal injection of recombinant human follicle-stimulating hormone (rhFSH)
Study: 34639109
Drug: Abdominal injection
Normalized name: PAD,ABDOMINAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abdominal injection of recombinant human follicle-stimulating hormone (rhFSH)
Study: 34639109
Drug: Daily abdominal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily abdominal or vaginal injections of rhFSH (1 IU twice daily for 4 days)
Study: 34639109
Drug: Intermittent vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent vaginal injections of rhFSH (4 IU every other day for two doses)
Study: 34639109
Drug: Intermittent abdominal
Normalized name: PAD,ABDOMINAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent abdominal or vaginal injections of rhFSH
Study: 34285426
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg bevacizumab and 1 mg intravitreal triamcinolone (combined treatment)
Study: 34029235
Drug: Eccentric exercises
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eccentric exercises with extracorporeal shockwave therapy (SWT group)
Study: 34029235
Drug: Eccentric exercises
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eccentric exercises with sham shockwave therapy (control group)
Study: 34301749
Drug: Physician's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician's choice chemotherapy (PC)
Study: 32186523
Drug: Desoximetasone spray
Normalized name: desoximetasone Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desoximetasone spray 0.25% for 2 weeks with twice-daily telephone call reminders
Study: 32186523
Drug: Desoximetasone spray
Normalized name: desoximetasone Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desoximetasone spray 0.25% for 2 weeks without reminders
Study: 35813434
Drug: Transesophageal ultrasound
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transesophageal ultrasound monitoring using ONLM algorithm with optimal pulmonary compliance titration of PEEP.
Study: 33070176
Drug: Isoniazid AUC
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid AUC >21.78 mg · h/L
Study: 33070176
Drug: Rifampicin AUC
Normalized name: rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifampicin AUC >82.01 mg · h/L
Study: 35785423
Drug: Hard splint
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hard splint therapy
Study: 35785423
Drug: Soft splint
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft splint therapy
Study: 33434035
Drug: Conidia suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conidia suspension with a concentration of 5×10^5/ml sprayed on fruits; maintained high humidity for 3 days
Study: 33252568
Drug: OA-CXL (accelerated
Approvals — FDA: no, EMA: no, PMDA: no
Description: OA-CXL (accelerated CXL with systemic oxygen at 5 L/min for 10 minutes)
Study: 35014128
Drug: Echocardiography-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Echocardiography-guided therapy with spironolactone
Study: 33351921
Drug: Lifestyle therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle therapy plus testosterone (LT+Test)
Study: 33351921
Drug: Lifestyle therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle therapy plus placebo (LT+Pbo)
Study: 32436455
Drug: Rivaroxaban 2.5
Normalized name: rivaroxaban 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 2.5 mg twice daily plus ASA 100 mg
Study: 32436455
Drug: ASA 100
Normalized name: ASA 100 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA 100 mg
Study: 38748321
Drug: Lemborexant 5
Normalized name: lemborexant 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lemborexant 5 mg (LEM5)
Study: 38748321
Drug: Lemborexant 10
Normalized name: lemborexant 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lemborexant 10 mg (LEM10)
Study: 32682347
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg melatonin taken 1 hour before desired bedtime for 4 weeks (5-7 nights/week)
Study: 34420834
Drug: Zonisamide 25
Normalized name: zonisamide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zonisamide 25 mg/day
Study: 32898787
Drug: Calorie-restricted diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calorie-restricted diet plus 109 CFU synbiotic supplement (CRS group; n = 45)
Study: 35715184
Drug: Elagolix 200
Normalized name: elagolix 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elagolix 200 mg two times per day for 8 weeks
Study: 32677855
Drug: Warfarin dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin dosing algorithm for patients older than 60
Study: 34126419
Drug: Shenhuang Granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenhuang Granule (SHG) administered twice a day for 14 days
Study: 33657757
Drug: Suit therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suit therapy
Study: 34424546
Drug: rhGH therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH therapy
Study: 32946574
Drug: SJX-653 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: SJX-653 30 mg
Study: 32946574
Drug: SJX-653 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: SJX-653 60 mg
Study: 33393484
Drug: Mindfulness meditation
Normalized name: benzalkonium chloride Topical Foam [Meditize]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness meditation (MM) for 3 weeks, 45-minute daily sessions
Study: 33128696
Drug: Disease-modifying anti-rheumatic
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disease-modifying anti-rheumatic drugs (DMARDs) and biologic agents
Study: 32456874
Drug: Gelatin sponge
Normalized name: ABSORBABLE GELATIN SPONGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelatin sponge patch
Study: 33004472
Drug: empagliflozin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: empagliflozin (25 mg)
Study: 33004472
Drug: LY2409021 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2409021 (300 mg)
Study: 35143872
Drug: Trimetazidine (TMZ)
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (TMZ) 5 mg/kg solution every two days by gavage for two weeks
Study: 35143872
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (conventional treatments)
Study: 35143872
Drug: Model group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Model group (D-gal 500 mg/kg intraperitoneal injection every two days for six weeks)
Study: 34396584
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL lidocaine (2%)
Study: 36050587
Drug: Online group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online group problem-solving therapy (PST)
Study: 36049147
Drug: encorafenib (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: encorafenib (450 mg orally once daily) plus binimetinib (45 mg orally twice daily) until progressive disease -> ipilimumab plus nivolumab (ipilimumab 3 mg/kg once every 3 weeks and nivolumab 1 mg/kg once every 3 weeks × four cycles -> nivolumab 3 mg/kg every 2 weeks)
Study: 33357217
Drug: Edoxaban (a
Normalized name: edoxaban (as tosylate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban (a direct oral anticoagulant)
Study: 32636043
Drug: Early mobilization
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early mobilization (E-MOB) with a removable orthosis and daily wrist exercises
Study: 32636043
Drug: Late mobilization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late mobilization (L-MOB) with a standard dorsal plaster cast for 2 weeks followed by a removable orthosis and exercises
Study: 32636043
Drug: Late mobilization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late mobilization (L-MOB)
Study: 35016497
Drug: TRLB (0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRLB (0.25% bupivacaine 0.4 ml/kg)
Study: 36386982
Drug: Risperidone treatment
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone treatment for 12 weeks
Study: 32078147
Drug: Intramuscular clodronate
Normalized name: Clodronic acid
DrugBank: Clodronic acid (DB00720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular clodronate 200 mg daily for 15 days and then once weekly for the next 11.5 months
Study: 32078147
Drug: Intramuscular clodronate
Normalized name: Clodronic acid
DrugBank: Clodronic acid (DB00720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular clodronate 200 mg daily for 15 days and then once weekly for the next 2.5 months
Study: 33373914
Drug: Placebo (P)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (P) inhalation
Study: 34325886
Drug: MitraClip plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: MitraClip plus guideline-directed medical therapy (GDMT)
Study: 32313032
Drug: MR stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: MR stimulation (0.4 mg fludrocortisone)
Study: 35717867
Drug: NMDA-R stimulation
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: NMDA-R stimulation (250 mg D-cycloserine)
Study: 33963372
Drug: Rosuvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (10 mg per day)
Study: 33963372
Drug: Blood pressure
Normalized name: Blood Pressure Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood pressure lowering treatment
Study: 32628547
Drug: Morphine Treatment
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine Treatment with Metoclopramide Coadministration
Study: 32628547
Drug: Morphine Treatment
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine Treatment without Metoclopramide Coadministration
Study: 33804824
Drug: Vaccine IBV
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine IBV strains
Study: 37596449
Drug: Cytoreductive surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)
Study: 36455453
Drug: PEA‐LUT 700
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEA‐LUT 700 mg + 70 mg
Study: 34992123
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of venous leg ulcers with community staff involvement
Study: 34399166
Drug: eNose analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: eNose analysis for early monitoring during anti-PD-1 therapy
Study: 33750646
Drug: SPN-812 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPN-812 200 mg
Study: 33750646
Drug: SPN-812 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPN-812 400 mg
Study: 33846037
Drug: Elevated CEA
Normalized name: Ad-CEA vaccine
DrugBank: Ad-CEA vaccine (DB17581)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated CEA levels before treatment
Study: 32692247
Drug: Whole brain
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole brain radiotherapy (WBRT) alone 300 cGy/fraction ×10 fractions, total dose 3,000 cGy
Study: 32692247
Drug: Whole brain
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole brain radiotherapy (WBRT) alone 180 cGy/fraction ×22 fractions, total dose 3,960 cGy
Study: 32692247
Drug: Intracranial metastases
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracranial metastases radiotherapy alone 250 cGy/fraction ×22 fractions, total dose 5,500 cGy
Study: 32692247
Drug: Whole brain
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole brain + intracranial metastases group (SIB) whole brain 180 cGy/fraction ×22 fractions, intracranial metastases 250 cGy/fraction ×22 fractions, total doses 3,960 cGy and 5,500 cGy respectively
Study: 34052007
Drug: Ivermectin (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (0.2 mg/kg single dose)
Study: 34912021
Drug: Split tablet
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Split tablet regimen (group S)
Study: 34544754
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of erector spinae block and retrolaminar block (10 mL each)
Study: 34544754
Drug: Erector spinae
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erector spinae block (20 mL)
Study: 36243227
Drug: Direct consultations
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct consultations with medical physicists during treatment simulation and before the first treatment.
Study: 35990583
Drug: Olaparib (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib (300 mg twice daily by mouth in 21-day cycles)
Study: 34983471
Drug: Viscosupplementation (single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viscosupplementation (single-dose intraarticular hyaluronic acid injection)
Study: 32037273
Drug: 30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg of methylprednisolone
Study: 32134035
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no surface treatment)
Study: 37062349
Drug: PAP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAP therapy with lifestyle counseling
Study: 36480147
Drug: Intravenous lysine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lysine acetylsalicylate (LA) 450 mg plus oral ticagrelor 180 mg
Study: 36480147
Drug: Oral aspirin
Normalized name: aspirin Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral aspirin 300 mg plus ticagrelor 180 mg
Study: 36480147
Drug: Intravenous lysine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lysine acetylsalicylate (LA)
Study: 38648030
Drug: Oral aspirin
Normalized name: aspirin Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral aspirin
Study: 32571870
Drug: Canakinumab 150
Normalized name: canakinumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canakinumab 150 or 300 mg, every 4 or 8 weeks during a 72-week period
Study: 35001562
Drug: No beta-blockers
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No beta-blockers (Control)
Study: 32492682
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of EBUS-SE (<115) with size (<8 mm) and FDG-PET information
Study: 32492682
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of size and SE
Study: 32245307
Drug: Guluronic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guluronic acid (G2013) administered orally at a dose of 500 mg twice daily for 12 weeks
Study: 34101934
Drug: NEPA plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: NEPA plus single-dose DEX (12 mg on day 1) with no further DEX (DEX1)